Molecular profiling and the impact of treatment on outcomes in adenoid cystic carcinoma (ACC) type-I and II.

Glenn J Hanna Punita Grover Andrew Elliott Julie E McGrath Joanne Xiu Ammar Sukari Jennifer M Johnson Trisha Michel Wise-Draper

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

We confirmed the previously reported associations with MYC and TP63 in the prognostically relevant subgroups of ACC-I and II, respectively, and report immunologic differences among these subtypes. Survival outcomes are comparatively worse in ACC-I regardless of treatment type.

Keyphrases